Navigation Links
Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
Date:11/2/2009

he first systemically administered siRNA, as well as additional pre-clinical stage compounds, through important value-enhancing milestones in 2010. We look forward to presenting these case studies reflecting the success of our proprietary programs."

QPI-1002 targets p53, a stress-response gene that plays a pivotal role in the apoptotic pathway. Temporary inhibition of p53 at the time of injury delays cell death, allowing natural repair mechanisms to restore normal DNA and cellular integrity. QPI-1002 is currently being evaluated in a Phase I/IIa clinical study for the prevention of acute kidney injury (AKI) and in Part A of a Phase I/II clinical study for the prophylaxis of delayed graft function (DGF) following renal transplantation. Both studies are scheduled to be completed this year.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to target tissues and organs including the eye, ear, lung, spinal cord and brain.

Quark's clinical pipeline includes PF-4523655 (RTP801i-14), currently in Phase II clinical trials for Diabetic Macular Edema (DME) and Age-related Macular Degeneration (AMD). PF-4523655 is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acu
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
2. Quark Pharmaceuticals Presents at Asia TIDES Conference
3. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  Air Products (NYSE: ... of medical oxygen is vital to any healthcare facility. ... that not only improve the efficiency of its oxygen ... will highlight these systems—including systems for emergency oxygen ... loss—from August 4-5 at the 51 st ...
(Date:7/28/2014)... 28, 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... that leads to inflammation and pain in the human body,s ... addition, it causes inflammation of the tissues that surround the ... symptoms of RA begin slowly, usually just mild pain around ...
(Date:7/28/2014)... , July 28, 2014  TNI BioTech, Inc. ... company focused on the development, marketing and distribution ... filed definitive proxy materials with the Securities and ... Meeting of Shareholders to be held on Thursday, ... Time. The record date for determining those shareholders ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Global Rheumatoid Arthritis Drugs Market 2014-2018 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3
... The U.S. Food and Drug Administration today announced that monthly ... Letairis tablets (ambrisentan), used to treat high blood pressure in ... hypertension, or PAH). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the FDA said that the drug poses only a low ...
... 4, 2011 Sigma-Aldrich Corporation (Nasdaq: SIAL ) ... 31st Annual Cowen and Company Healthcare Conference ... Place, Boston, MA, presenting at 10:15 AM (EST). Barclays ... the Loews Miami Hotel, Miami, FL, presenting at 10:15 AM ...
Cached Medicine Technology:FDA Modifies Boxed Warning For Pulmonary Arterial Hypertension Drug Letairis 2FDA Modifies Boxed Warning For Pulmonary Arterial Hypertension Drug Letairis 3
(Date:7/28/2014)... 29, 2014 The “Tissue ... Hybridization, Digital pathology & Workflow, Special Staining), ... Cancer, Non Small Cell Lung Cancer and ... Pharmaceutical companies, Research Laboratories, Contract Research Organizations ... Europe, BRIC, Japan & RoW) - Trends ...
(Date:7/28/2014)... Ariz (PRWEB) July 28, 2014 ... on a new camp property in Cornville, AZ. ... seriously ill children with the opportunity to attend ... campers and families. The organization offers a variety ... 6-15 with chronic and life threatening illnesses including: ...
(Date:7/28/2014)... 28, 2014 An estimated 68,000 women ... metastatic breast and prostate cancers – an aggressive form ... spread to other parts of the body, such as ... Drexel University College of Medicine have developed ... inhibits metastatic progression by blocking tumor cells from “re-seeding.” ...
(Date:7/28/2014)... a surgical procedure to treat severe chronic migraine headaches ... of the time in patients treated at Massachusetts General ... Plastic and Reconstructive Surgery report that more than half ... all of whom had headaches associated with compression of ... later. The team,s paper has received advance online ...
(Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
Breaking Medicine News(10 mins):Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... the blood is not associated with a reduced risk ... online May 27 in the Journal of the ... high doses of vitamin D may reduce the risk ... the relationship have reported inconsistent results. , In a ...
... finds evidence of slight link between higher concentrations, aggressive ... Men with a high blood concentration of vitamin D ... Cancer Institute researchers report. , Previous laboratory studies had ... prostate cancer risk, but epidemiological studies of that association ...
... Researchers have uncovered a completely unexpected way that the brain ... protective protein to nearby neurons. , Astrocytes are a type ... one of their roles is to chew up damaged nerves ... damaged area. , Roger Chung and colleagues have now ...
... higher in low-expenditure areas than in high-expenditure ones, study ... levels of spending on medical care don,t improve patients, ... who conducted a survey of Medicare beneficiaries. , Per ... United States and differences in health don,t account for ...
... review suggests they may help cancer cells resist chemo, ... new review of existing research suggests that cancer patients ... of antioxidants. , Although multivitamins may be all right ... or E supplements can spell trouble, said review author ...
... Environmentally friendly is not a phrase normally used to ... discovery at Tel Aviv University, the chemical industry is ... Arkadi Vigalok from the School of Chemistry at Tel ... to make certain steps of a complicated chain of ...
Cached Medicine News:Health News:No association found between vitamin D concentration in blood and risk of prostate cancer 2Health News:Vitamin D Status Not Associated With Lower Prostate Risk 2Health News:Spending Doesn't Improve Patients' Perception of Care 2Health News:Cancer Patients Should Steer Clear of Antioxidants 2Health News:Cancer Patients Should Steer Clear of Antioxidants 3Health News:1 small step for a lab science, 1 green leap for mankind 2
... to use: when presented in convenient, ... easy to pick up directly from ... the 96 tips are loaded without ... with a security sticker. Fully autoclavable, ...
This pipette tip facilitates the loading of samples onto polyacrylamide gels for DNA sequencing. The Geloader Tip has a 15 mm capillary with a defined diameter of less than 0.3 mm. The flexibility of...
1200 L, Racked, 96 tips/rack, 10 racks/box Recommended for 1200 L SofTouch electronic pipettes....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
Medicine Products: